Bladex (BLX) Could Be 15% Undervalued Following Its Biggest Panama Loan Deal

Bladex (BLX) has become a focal point for investors after arranging a senior loan facility of up to US$1.0b for the Republic of Panama. This is its largest structured transaction to date.

That US$1.0b Panama facility lands at a moment when Bladex’s share price has already moved sharply higher this year, with a year-to-date share price return of 26.68% and a 1-year total shareholder return of 27.30%. The 3-year total shareholder return of more than 2x and the 5-year total shareholder return of more than 3x suggest momentum has been building over a longer horizon.

Scan other trade finance and regional lenders showing similar momentum and balance sheet strength through our curated list of list of solid balance sheet and fundamentals (25 results) to benchmark Bladex in context.

Bladex now trades well above where it started the year and is fresh off its largest transaction yet. Is it better to pay a higher price today or wait for a calmer entry before judging the valuation?

Most Popular Narrative: 15% Undervalued

Bladex’s most followed valuation story pegs fair value at about $65.53, above the last close of $55.51. The narrative still frames the recent share price strength as leaving room on the table.

The rollout of a new digital trade finance platform positions Bladex to significantly increase transaction volumes, improve client retention, and expand service offerings to underbanked SMEs. This is described as a potential driver for fee income, revenue growth, and enhanced operational efficiency over the coming 18 months. Structural growth in intra Latin American trade and new regional trade agreements are expected to raise demand for cross border financing, supporting loan book growth, increased fee income from letters of credit, and potential market share gains, which is seen as positively impacting revenues and earnings.

See why 15 investors see Bladex as 15% undervalued.

Result: Fair Value of $65.53 (UNDERVALUED)

Still, the Bladex story can change quickly if regional sovereign stress affects asset quality or if large, one off deals fail to repeat.

Find out about the key risks to this Bladex narrative.

Next Steps

Sentiment on Bladex is mixed enough to keep debate alive. Move quickly, review the full picture yourself, and weigh both the upside and downside by checking 4 key rewards and 1 important warning sign.

Looking for more Bladex investment ideas?

If you like the Bladex story but do not want all your capital tied to one ticker, spread your research across a few focused shortlists that surface different strengths.

• Target resilient balance sheets by scanning a curated list of solid balance sheet and fundamentals (25 results) that filters for companies with financial footing you can analyse with greater confidence.
• Hunt for mispriced quality using the 32 high quality undervalued stocks that highlights businesses where fundamentals and current pricing appear out of sync.
• Build a cash flow focused watchlist through the 6 dividend fortresses and keep an eye on companies returning meaningful income to shareholders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com